BKS Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

BKS Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$20K	Hold	15,000	–	–	0.01%	207
2018 Q4	$14K	Sell	15,000 -2,145	-13%	-$3.29K	0.01%	196
2018 Q3	$35K	Hold	17,145	–	–	0.01%	217
2018 Q2	$31K	Hold	17,145	–	–	0.01%	231
2018 Q1	$40K	Buy	+17,145	New	+$40.2K	0.01%	214
2017 Q4	–	Sell	-11,430	Closed	-$28K	–	217
2017 Q3	$28K	Hold	11,430	–	–	0.01%	209
2017 Q2	$32K	Hold	11,430	–	–	0.01%	203
2017 Q1	$35K	Hold	11,430	–	–	0.02%	194
2016 Q4	$36K	Hold	11,430	–	–	0.02%	182
2016 Q3	$39K	Hold	11,430	–	–	0.02%	235
2016 Q2	$26K	Hold	11,430	–	–	0.01%	174
2016 Q1	$29K	Sell	11,430 -960	-8%	-$2.14K	0.02%	167
2015 Q4	$41K	Buy	+12,390	New	+$37K	0.02%	152

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

BKS Advisors's LCTX Position: Q1 2019 in Review

BKS Advisors held its Lineage Cell Therapeutics (LCTX) position steady in Q1 2019 at 15,000 shares worth $20K. The position accounts for 0.01% of the portfolio, ranked #207.

BKS Advisors first reported a position in LCTX in Q4 2015 and has held it in 13 quarters since. The position peaked at $41K in Q4 2015. 118 funds tracked by Wall St. Rank hold LCTX as of Q1 2019.

BKS Advisors held 15,000 shares of Lineage Cell Therapeutics worth $20K as of Q1 2019.
BKS Advisors left its Lineage Cell Therapeutics share count unchanged in Q1 2019.
Lineage Cell Therapeutics made up 0.01% of BKS Advisors's portfolio in Q1 2019, its #207 holding.
BKS Advisors first reported a position in Lineage Cell Therapeutics in Q4 2015 and has held it in 13 quarters since.
BKS Advisors's Lineage Cell Therapeutics position peaked at $41K in Q4 2015.
118 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2019.

Based on BKS Advisors's 13F filing for Q1 2019, filed 16 Apr 2019.